|
1
|
Papaemmanuil E, Gerstung M, Malcovati L,
Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC,
Pellagatti A, et al: Clinical and biological implications of driver
mutations in myelodysplastic syndromes. Blood. 122:3616–3627.
36992013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Odenike O, Anastasi J and Le Beau MM:
Myelodysplastic Syndromes. Clin Lab Med. 31:763–784. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foucar K:
Myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol.
132:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dayyani F, Conley AP, Strom SS, Stevenson
W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S,
Kantarjian H and Garcia-Manero G: Cause of death in patients with
lower-risk myelodysplastic syndrome. Cancer. 116:2174–2179.
2010.PubMed/NCBI
|
|
5
|
Garcia-Manero G: Myelodysplastic
syndromes: 2014 Update on diagnosis, risk-stratification, and
management. Am J Hematol. 89:97–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Price DJ, Miralem T, Jiang S, Steinberg R
and Avraham H: Role of vascular endothelial growth factor in the
stimulation of cellular invasion and signaling of breast cancer
cells. Cell Growth Differ. 12:129–135. 2001.PubMed/NCBI
|
|
7
|
Podar K and Anderson KC: The
pathophysiologic role of VEGF in hematologic malignancies:
Therapeutic implications. Blood. 105:1383–1395. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee TH, Seng S, Sekine M, Hinton C, Fu Y,
Avraham HK and Avraham S: Vascular endothelial growth factor
mediates intracrine survival in human breast carcinoma cells
through internally expressed VEGFR1/FLT1. PLoS Med. 4:e1862007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adams RH and Alitalo K: Molecular
regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell
Biol. 8:464–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Veikkola T, Karkkainen M, Claesson-Welsh L
and Alitalo K: Regulation of angiogenesis via vascular endothelial
growth factor receptors. Cancer Res. 60:203–212. 2000.PubMed/NCBI
|
|
11
|
Vincent L, Jin DK, Karajannis MA, Shido K,
Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, et al:
Fetal stromal-dependent paracrine and intracrine vascular
endothelial growth factor-a/vascular endothelial growth factor
receptor-1 signaling promotes proliferation and motility of human
primary myeloma cells. Cancer Res. 65:3185–3192. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z,
Hicklin DJ and Moore MA: Targeting autocrine and paracrine VEGF
receptor pathways inhibits human lymphoma xenografts in vivo.
Blood. 104:2893–2902. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boiocchi L, Vener C, Savi F, Bonoldi E,
Moro A, Fracchiolla NS, Iurlo A, Deliliers GL, Coggi G, Bosari S
and Gianelli U: Increased expression of vascular endothelial growth
factor receptor 1 correlates with VEGF and microvessel density in
Philadelphia chromosomenegative myeloproliferative neoplasms. J
Clin Pathol. 64:226–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bellamy WT, Richter L, Sirjani D, Roxas C,
Glinsmann-Gibson B, Frutiger Y, Grogan TM and List AF: Vascular
endothelial cell growth factor is an autocrine promoter of abnormal
localized immature myeloid precursors and leukemia progenitor
formation in myelodysplastic syndromes. Blood. 97:1427–1434. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wimazal F, Krauth MT, Vales A, Böhm A,
Agis H, Sonneck K, Aichberger KJ, Mayerhofer M, Simonitsch-Klupp I,
Müllauer L, et al: Immunohistochemical detection of vascular
endothelial growth factor (VEGF) in the bone marrow in patients
with myelodysplastic syndromes: Correlation between VEGF expression
and the FAB category. Leuk Lymphoma. 47:451–460. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aguayo A, Kantarjian HM, Estey EH, Giles
FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ and
Albitar M: Plasma vascular endothelial growth factor levels have
prognostic significance in patients with acute myeloid leukemia but
not in patients with myelodysplastic syndromes. Cancer.
95:1923–1930. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verstovsek S, Estey E, Manshouri T, Giles
FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H and
Albitar M: Clinical relevance of vascular endothelial growth factor
receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic
syndrome. Br J Haematol. 118:151–156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su JL, Yen CJ, Chen PS, Chuang SE, Hong
CC, Kuo IH, Chen HY, Hung MC and Kuo ML: The role of the
VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96:541–545.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J: WHO Classification of Tumors of
Haematopoietic and Lymphoid Tissues. Revised 4th edition. IARC;
Lyon: 2017
|
|
20
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shaffer LG, Slovak ML and Campbell LJ:
ISCN 2009: An international system for human cytogenetic
nomenclature (2009). Basel, Switzerland: S. Karger; 2009
|
|
22
|
Kalitin NN and Buravtsova IV:
Transcription factor RARa expression correlates with
VEGFR3-dependent signaling system components expression in multiple
myeloma. Klinicheskaya Onkogematologiya. 8:31–36. 2015.(In
Russian).
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dor Y, Porat R and Keshet E: Vascular
endothelial growth factor and vascular adjustments to perturbations
in oxygen homeostasis. Am J Physiol Cell Physiol. 280:C1367–C1374.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wimazal F, Sperr WR, Kundi M, Meidlinger
P, Fonatsch C, Jordan JH, Thalhammer-Scherrer R, Schwarzinger I,
Geissler K, Lechner K and Valent P: Prognostic value of lactate
dehydrogenase activity in myelodysplastic syndromes. Leuk Res.
25:287–294. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Naqvi K, Jabbour E, Bueso-Ramos C, Pierce
S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H and
Garcia-Manero G: Implications of discrepancy in morphologic
diagnosis of myelodysplastic syndrome between referral and tertiary
care centers. Blood. 118:4690–4693. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mufti GJ, Bennett JM, Goasguen J, Bain BJ,
Baumann I, Brunning R, Cazzola M, Fenaux P, Germing U,
Hellström-Lindberg E, et al: Diagnosis and classification of
myelodysplastic syndrome: International working group on morphology
of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the
definition and enumeration of myeloblasts and ring sideroblasts.
Haematologica. 93:1712–1717. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Montalban-Bravo G and Garcia-Manero G:
Myelodysplastic syndromes: 2018 Update on diagnosis,
risk-stratification and management. Am J Hematol. 93:129–147. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda
M, Hayashi Y, Watanabe Y and Sasaki T: Significance of vascular
endothelial growth factor messenger RNA expression in primary lung
cancer. Clin Cancer Res. 2:1411–1416. 1996.PubMed/NCBI
|
|
31
|
Fontanini G, Bigini D, Vignati S, Basolo
F, Mussi A, Lucchi M, Chine S, Angeletti CA, Harris AL and
Bevilacqua G: Microvessel count predicts metastatic disease and
survival in non-small cell lung cancer. J Pathol. 177:57–63. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meitar D, Crawford SE, Rademaker AW and
Cohn SL: Tumor angiogenesis correlates with metastatic disease,
N-myc amplification, and poor outcome in human neuroblastoma. J
Clin Oncol. 14:405–414. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
O'Brien T, Cranston D, Fuggle S, Bicknell
R and Harris AL: Different angiogenic pathways characterize
superficial and invasive bladder cancer. Cancer Res. 55:510–513.
1995.PubMed/NCBI
|
|
34
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity, metastasis, and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
|
35
|
Anan K, Morisaki T, Katano M, Ikubo A,
Kitsuki H, Uchiyama A, Kuroki S, Tanaka M and Torisu M: Vascular
endothelial growth factor and platelet-derived growth factor are
potential angiogenic and metastatic factors in human breast cancer.
Surgery. 119:333–339. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pruneri G, Bertolini F, Soligo D, Carboni
N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G and
Pezzella F: Angiogenesis in myelodysplastic syndromes. Br J Cancer.
81:1398–1401. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Legros L, Slama B, Karsenti JM, Vey N,
Natarajan-Amé S, Watel E, Richard B, Bouabdallah K, Mannone L,
Benchetrit M, et al: Treatment of myelodysplastic syndromes with
excess of blasts by bevacizumab is well tolerated and is associated
with a decrease of VEGF plasma level. Ann Hematol. 91:39–46. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giles FJ, Stopeck AT, Silverman LR, Lancet
JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA,
Louie SG, et al: SU5416, a small molecule tyrosine kinase receptor
inhibitor, has biologic activity in patients with refractory acute
myeloid leukemia or myelodysplastic syndromes. Blood. 102:795–801.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Giles FJ, Bellamy WT, Estrov Z, O'Brien
SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y,
Steinfeldt H, et al: The anti-angiogenesis agent, AG-013736, has
minimal activity in elderly patients with poor prognosis acute
myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res.
30:801–811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gupta P, Mulkey F, Hasserjian RP, Sanford
BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM,
et al: A phase II study of the oral VEGF receptor tyrosine kinase
inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome:
Cancer and leukemia group B study 10105 (alliance). Invest New
Drugs. 31:1311–1320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kirschbaum MH, Frankel P, Synold TW, Zain
J, Claxton D, Tuscano J, Newman EM, Gandara DR and Lara PN Jr: A
phase II study of vascular endothelial growth factor trap
(Aflibercept, NSC 724770) in patients with myelodysplastic
syndrome: A California cancer consortium study. Br J Haematol.
180:445–448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen
CY, Tang JL, Chou WC, Tseng MH, Yao M, Huang SY, et al: High bone
marrow angiopoietin-1 expression is an independent poor prognostic
factor for survival in patients with myelodysplastic syndromes. Br
J Cancer. 105:975–982. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shalaby F, Rossant J, Yamaguchi T,
Gertsenstein M, Wu XF, Breitman ML and Schuh AC: Failure of
blood-island formation and vasculogenesis in Flk-1-deficient mice.
Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Eichmann A, Corbel C, Nataf V, Vaigot P,
Bréant C and Le Douarin NM: Ligand-dependent development of the
endothelial and hemopoietic lineages from embryonic mesodermal
cells expressing vascular endothelial growth factor receptor 2.
Proc Natl Acad Sci USA. 94:5141–5146. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carrillo de Santa PE, Arias FC, Caso
Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I,
Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A and del
Val Toledo Lobo M: Prognostic significance of the expression of
vascular endothelial growth factors A, B, C, and D and their
receptors R1, R2, and R3 in patients with non-small cell lung
cancer. Cancer. 115:1701–1712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ock CY, Nam AR, Bang JH, Kim TY, Lee KH,
Han SW, Im SA, Kim TY, Bang YJ and Oh DY: The distinct signatures
of VEGF and soluble VEGFR2 increase prognostic implication in
gastric cancer. Am J Cancer Res. 5:3376–3388. 2015.PubMed/NCBI
|
|
47
|
Dhakal HP, Naume B, Synnestvedt M, Borgen
E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R,
Giercksky KE and Nesland JM: Expression of vascular endothelial
growth factor and vascular endothelial growth factor receptors 1
and 2 in invasive breast carcinoma: Prognostic significance and
relationship with markers for aggressiveness. Histopathology.
61:350–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kalitin NN, Dudina GA, Semochkin SV and
Karamysheva AF: Analysis of VEGF-A/VEGFR1/VEGFR2 genes expression
analyses in patients with myelodysplastic syndromes. Ther Arch.
89:39–44. 2017.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
